Oruka Therapeutics Reports Strong Clinical Progress for Lead Programs & Secures Over $200M in New Capital

summarizeSummary

Oruka Therapeutics announced positive clinical trial progress for its lead programs ORKA-001 and ORKA-002, coupled with successful capital raises totaling over $200 million, extending its cash runway for at least 12 months.

check_boxKey Events

• Clinical Pipeline Advancement

  Lead program ORKA-001 (IL-23p19) is progressing with Phase 2a dosing commenced in Q3 2025 and Phase 2b dosing initiated in December 2025. Co-lead program ORKA-002 (IL-17A/F) initiated a Phase 2 trial in February 2026, with a Phase 2 trial for hidradenitis suppurativa (HS) expected in H2 2026. Both programs demonstrate promising early data, including extended half-lives.

• Significant Capital Raises

  The company secured $169.6 million in net proceeds from a PIPE financing in September 2025. Additionally, subsequent to year-end, Oruka sold 1,167,895 shares through its ATM program at an average price of $33.99, generating $38.9 million in net proceeds.

• Extended Cash Runway

  As of December 31, 2025, Oruka Therapeutics held $479.6 million in cash, cash equivalents, and marketable securities, which is projected to fund operating plans for at least the next twelve months.

• Increased Net Loss

  The net loss for the year ended December 31, 2025, increased to $105.4 million, up from $83.7 million for the period from February 6, 2024 (inception) to December 31, 2024, reflecting increased research and development expenses as the pipeline advances.

auto_awesomeAnalysis

Oruka Therapeutics, a clinical-stage biopharmaceutical company, has reported significant advancements in its lead programs, ORKA-001 and ORKA-002, which are monoclonal antibody therapeutics for inflammatory and immunology indications. Both programs have shown promising early clinical data, including extended half-lives, and are progressing into later-stage trials. The company also successfully raised substantial capital, including $169.6 million from a PIPE financing in September 2025 and an additional $38.9 million from an at-the-market (ATM) offering post-year-end, totaling over $200 million. This capital infusion, alongside existing cash, is expected to fund operations for at least the next twelve months, which is critical for a clinical-stage biotech. While net losses increased, this is typical for a company with an advancing pipeline. A new risk factor regarding the BIOSECURE Act and its potential impact on foreign manufacturing relationships, such as with WuXi Biologics, has been disclosed.